| Prev Close: | 84.23 |
|---|---|
| Open: | 84.35 |
| Bid: | 84.91 x 1100 |
| Ask: | 84.92 x 2000 |
| 1y Target Est: | 86.50 |
| Beta: | 0.47 |
| Next Earnings Date: | 15-Jul-13 |
| Day's Range: | 84.17 - 85.00 |
|---|---|
| 52wk Range: | 61.71 - 85.89 |
| Volume: | 5,195,888 |
| Avg Vol (3m): | 9,711,360 |
| Market Cap: | 237.38B |
| P/E (ttm): | 23.06 |
| EPS (ttm): | 3.68 |
| Div & Yield: | 2.64 (3.10%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- The 10 most overbought names in the S&P 500at MarketWatch(Thu 12:55PM EDT)
- Blue Chip Stocks Fetch Ridiculous Valuations, But Don't Sell Just Because It's Mayat Forbes(Thu 12:37PM EDT)
- Decades-old question: Is anti-bacterial soap safe?AP(Thu 12:37PM EDT)
- Decade-old question: Is anti-bacterial soap safe?AP(Thu 12:06PM EDT)
- Decade-old question: Is antibacterial soap safe?AP(Thu 11:57AM EDT)
- Has Krugman Really Won?at Seeking Alpha(Thu 10:45AM EDT)
- Why You Should Buy This Blue Chip Stockat Motley Fool(Thu 10:10AM EDT)
- The Stock Buffett Ought to Be Bragging AboutYCharts(Thu 10:06AM EDT)
- Why Apple Is Just Not a Growth Stock Anymoreat Motley Fool(Thu 9:23AM EDT)
- Time To Be A Contrarian?at Seeking Alpha(Thu 9:01AM EDT)
- Is PepsiCo Still A Great Stock To Buy Now?at Motley Fool(Thu 8:45AM EDT)
- Genmab Rises After FDA Grants Breakthrough Status to Cancer Drugat Bloomberg(Thu 5:13AM EDT)
- UPDATE 1-Smith & Nephew unveils $300 mln share buybackat Reuters(Thu 2:58AM EDT)
- Vertex Q1 Results Worse Than 2012, but Better Than Expectedat Motley Fool(Thu 2:06AM EDT)
- Johnson & Johnson: Blue Chip Chaser Vs. The Value Hunterat Seeking Alpha(Thu 1:06AM EDT)
Press Releases
- Johnson & Johnson Announces Dividend Increase of 8.2%PR Newswire(Thu, Apr 25)
- Johnson & Johnson to Host Pharmaceuticals Business ReviewPR Newswire(Tue, Apr 23)
- Johnson & Johnson Announces Sale of Elan American Depositary Shares to ElanPR Newswire(Thu, Apr 18)
Reports
- JNJ: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- JNJ - Johnson & Johnson - Downgraded to a Sell - Research Report by ASRAlpha Street Research(Apr 29)
- Trading Report for (JNJ). A detailed report, including free correlated market...Stock Traders Daily(May 2)